This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Björn Frendéus, Ph.D.
Chief Scientific Officer at BioInvent International AB

Profile

Björn Frendéus is the CSO of BioInvent, a Swedish Biotech developing antibody-based treatments for cancer immunotherapy. Over the past decades he has developed a strong interest in understanding the complex biology of antibodies in relation to their targets, applying his knowledge to develop better antibody-based medicines. Björn’s team developed the F.I.R.S.T™ platform from which BioInvent’s current pipeline including clinical stage anti-FcgRIIB (BI-1206 and BI-1607), anti-TNFR2 program (BI-1808), BT-001 (oncovirally encoded anti-CTLA-4 IgG, Transgene collaboration) and anti-TAM (Pfizer collaboration) programs have emerged. Björn is a visiting professor at the Cancer Sciences Division in Southampton, UK and chairs SSF’s expert review committee on Infection Biology.

Agenda Sessions

  • FcR and Antibody Effector Functions

    12:15pm
  • Targeting and Tailoring Antibody-FcgR Interactions to Enhance Cancer Immunotherapy

    On Demand

Speakers at this event